Roche Holding AG Revenue 2006-2019 | RHHBY

Roche Holding AG annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Roche Holding AG revenue for the quarter ending December 31, 2019 was $M, a NAN% increase year-over-year.
  • Roche Holding AG revenue for the twelve months ending December 31, 2019 was $0M, a NAN% increase year-over-year.
  • Roche Holding AG annual revenue for 2019 was $64.165B, a 5.48% increase from 2018.
  • Roche Holding AG annual revenue for 2018 was $60.83B, a 7.37% increase from 2017.
  • Roche Holding AG annual revenue for 2017 was $56.655B, a 6.01% increase from 2016.
Roche Holding AG Annual Revenue
(Millions of US $)
2019 $64,165
2018 $60,830
2017 $56,655
2016 $53,441
2015 $52,454
2014 $54,568
2013 $52,477
2012 $50,627
2011 $49,949
2010 $45,622
2009 $45,304
2008 $42,241
2007 $40,346
2006 $34,702
2005 $24,998
Roche Holding AG Quarterly Revenue
(Millions of US $)
2019-12-31
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-12-31
2015-06-30
2014-12-31
2014-06-30
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
2011-06-30
2010-12-31
2010-06-30
2009-12-31
2009-06-30
2008-12-31
2008-06-30
2007-12-31
2007-09-30 $1,733
2007-06-30
2006-12-31
2006-06-30
2005-12-31
2005-06-30
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $265.584B $61.869B
Roche Holding AG is a research-based, product-focused organization dedicated to the discovery and early clinical development of pharmaceuticals and drugs, fine chemicals and vitamins, fragrances and flavors, diagnostic equipment and liquid crystals. The Company distributes its products throughout Europe, the United States, Asia and Latin America.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $333.683B 14.58
Merck (MRK) United States $186.492B 14.17
Novartis AG (NVS) Switzerland $182.748B 15.22
Pfizer (PFE) United States $176.138B 10.76
Novo Nordisk (NVO) Denmark $134.408B 23.07
Eli Lilly (LLY) United States $128.578B 22.24
Bristol-Myers Squibb (BMY) United States $117.955B 11.19
AstraZeneca (AZN) United Kingdom $111.168B 23.93
AbbVie (ABBV) United States $109.023B 8.26
Sanofi (SNY) France $107.553B 12.78
GlaxoSmithKline (GSK) United Kingdom $92.949B 11.79
Bayer (BAYRY) Germany $53.155B 7.66
H Lundbeck (HLUYY) Denmark $5.819B 10.11